Login / Signup

Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program.

Vishal VashisthaEvangelia KatsoulakisAixia GuoMeghan J PriceSara AhmedMichael J Kelley
Published in: JCO precision oncology (2023)
Although administration of off-label TAs is infrequent after CGP, more than one quarter of treatment regimens led to response. TAs associated with level 4 annotations lead to worse outcomes than TAs bearing higher levels of evidence.
Keyphrases
  • palliative care
  • type diabetes
  • metabolic syndrome
  • adipose tissue
  • single molecule
  • light emitting